Cancer News and Research

Latest Cancer News and Research

Winter months presents a good opportunity to test our homes for radon

Keeping our homes more tightly closed during the winter months allows indoor air pollutants to build up in higher concentrations. It presents a good opportunity to test our homes for radon, a colourless, odourless gas that is produced from the natural breakdown of uranium in rocks and soil.

9 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

New iPhone application offers videos from a wide range of health topics

icyou today announced the launch of its iPhone app. Available for free on Apple's iPhone App Store, the application gives users convenient access to important health information when and where they choose. icyou Health Video for iPhone is available as a free download from Apple's App Store on iPhone and iPod touch or at www.itunes.com/appstore/.

9 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

Time frame for parents to begin toilet training lessons for children

Researchers at The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and UMDNJ-Robert Wood Johnson Medical School (UMDNJ-RWJMS) have completed a study that pinpoints the period between 24 and 32 months of age as most effective time frame for parents to begin toilet training lessons with their children.

9 Jan 2010

Sudden Cardiac Arrest Foundation announces first virtual affiliate of its National Survivor Network

The Sudden Cardiac Arrest Foundation announced today the first virtual affiliate of its National Survivor Network(TM) at the National Association of EMS Physicians annual conference.

9 Jan 2010

Texas A&M professor studies new medical imaging methods to enhance cancer detection

Thanks to medical imaging techniques such as X-ray CT, ultrasound imaging and MRI, doctors have long been able to see to varying degrees what's going on inside a patient's body, and now a Texas A&M University mathematician is trying to find new and better ways to do so.

9 Jan 2010

ChromoCure announces interim stockholder guidance on upcoming events

ChromoCure, Inc. announced today interim stockholder guidance on upcoming events. Full details on the below items will be released in the coming days.

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Ochsner Health System to acquire NSRMC

The private, not-for-profit Ochsner Health System today announced the signing of a definitive agreement to purchase NorthShore Regional Medical Center (NSRMC), the ambulatory surgery center and several pieces of property on which the facility is located in Slidell, Louisiana. The projected closing date is April 1, 2010: this purchase will expand Ochsner Health System to eight hospitals in Southeast Louisiana. The medical staff will remain "open," which is consistent with how the facility operates today.

9 Jan 2010

FDA yet to review MannKind’s NDA for insulin therapy

MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind’s new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.

9 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010

St. Andrews Country Club hosts 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer

St. Andrews Country Club of Boca Raton members teamed up with LPGA Tour player Morgan Pressel this week to raise $405,000 through the 3rd annual 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer through early detection and treatment.

9 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.

8 Jan 2010

Synta Pharmaceuticals announces pricing of public offering of shares

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

8 Jan 2010

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

John C. Lechleiter, PhD, Chairman, President & CEO, Eli Lilly and Company, will deliver a keynote address, "Lifespans and Livelihoods: The Human Dimensions of Medical Innovation," to TOWN HALL Los Angeles on Thursday, January 14, 2010 at the Millennium Biltmore Hotel.

8 Jan 2010

Cancer News and Research

Latest Cancer News and Research

Winter months presents a good opportunity to test our homes for radon

Research determines and validates the efficacy of T category in IASLC's Staging Manual

New iPhone application offers videos from a wide range of health topics

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Time frame for parents to begin toilet training lessons for children

Sudden Cardiac Arrest Foundation announces first virtual affiliate of its National Survivor Network

Texas A&M professor studies new medical imaging methods to enhance cancer detection

ChromoCure announces interim stockholder guidance on upcoming events

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Ochsner Health System to acquire NSRMC

FDA yet to review MannKind’s NDA for insulin therapy

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Cancer Research UK scientists named on New Year's Honours list

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

St. Andrews Country Club hosts 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer

Genentech's ACTEMRA approved to treat RA

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

Synta Pharmaceuticals announces pricing of public offering of shares

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Newsletters you may be interested in